Fairooz Kabbinavar
Technik-/Wissenschafts-/F&E-Leiter bei CARDIFF ONCOLOGY, INC.
Vermögen: - $ am 30.04.2024
Profil
Fairooz Kabbinavar is currently the Chief Medical Officer at Cardiff Oncology, Inc. Prior to this, Dr. Kabbinavar held the position of Senior Vice President-Clinical Development at Tocagen, Inc. Dr. Kabbinavar also served as a Professor at the University of California, Los Angeles from 1991 to 2016.
Additionally, Dr. Kabbinavar was the Head-Global Research & Development at HUYA Bioscience International LLC from 2021 to 2023.
Dr. Kabbinavar obtained undergraduate and doctorate degrees from Nagpur University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CARDIFF ONCOLOGY, INC.
-.--% | 22.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Fairooz Kabbinavar
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.01.2023 |
Ehemalige bekannte Positionen von Fairooz Kabbinavar
| Unternehmen | Position | Ende |
|---|---|---|
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.02.2023 |
| University of California, Los Angeles | Corporate Officer/Principal | 01.10.2016 |
| FORTE BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Fairooz Kabbinavar
| Nagpur University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARDIFF ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
